News | January 27, 2026
Hester receives manufacturing license for inactivated avian influenza vaccine for poultry
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
The companies plan to start a pivotal Phase 3 trial in the coming months
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
PM emphasises the need to enhance lab surveillance & testing of all Severe Acute Respiratory Illness (SARI) cases & ramp up genome sequencing
KRIVIDA TRIVUS detects the specific virus causing a respiratory infection.
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The team will also assist the state health departments in terms of public health measures, management guidelines and protocols to manage the increasing cases of Avian Influenza
Subscribe To Our Newsletter & Stay Updated
